<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323776</url>
  </required_header>
  <id_info>
    <org_study_id>14-28-03/09</org_study_id>
    <nct_id>NCT02323776</nct_id>
  </id_info>
  <brief_title>Defining the Radiotherapy Dose and Volume Parameters Affecting Postoperative Complications in Esophageal Cancer Patients</brief_title>
  <official_title>Correlation of Radiotherapy-related Features With Postoperative Complications in Patients With Esophageal Cancer Treated With Trimodality Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify features of the cumulative dose-volume histogram&#xD;
      (DVH) for patients treated with trimodality therapy in oesophageal cancer and correlate these&#xD;
      with postoperative complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intention to treat analysis in patients initially assigned to be treated with the trimodality&#xD;
      protocol: neoadjuvant chemoradiotherapy followed by surgery.&#xD;
&#xD;
      The investigators will retrospectively evaluate several parameters of the treatment planning&#xD;
      of patients treated with a preoperative regimen (CROSS regimen 41,4 Gy in 23 fractions or 50,&#xD;
      4 Gy in 28 fractions ):&#xD;
&#xD;
        -  PTV volume1&#xD;
&#xD;
        -  MLD, V30, V20, V15, V10, VS5 (Volume lung less dan 5 Gy)2 (lung toxicity)&#xD;
&#xD;
        -  MHD, V20, V30, V403 (heart toxicity)&#xD;
&#xD;
        -  Mean stomach dose, V50 stomach&#xD;
&#xD;
        -  Mitochondrial DNA if available per patient Pre-existing cardiac,pulmonary comorbidity,&#xD;
           smoking behavior, BMI, type of surgery and chemotherapy (especially taxanes) will be&#xD;
           scored and take into account in a multivariate analysis. The investigators will collect&#xD;
           these data and correlate the data with the presence of postoperative complications, time&#xD;
           of onset of complications and duration of hospitalization. These latter data are already&#xD;
           scored in a prospective manner at the Atrium Medical Center in Heerlen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>within 30 and 90 Days after operation</time_frame>
    <description>Cardiac complications (arrhythmia etc )&#xD;
Respiratory complications (pneumonia, pleural effusion etc)&#xD;
Anastomotic leakage&#xD;
Postoperative 30-day mortality&#xD;
Total postoperative mortality&#xD;
Treatment-related mortality&#xD;
Hospitalization and stay at intensive care unit duration</description>
  </primary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Trimodality protocol</intervention_name>
    <description>neoadjuvant chemoradiotherapy followed by surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Oesophageal cancer patients who were initially treated with a preoperative dose of&#xD;
        radiation in combination with chemotherapy and who subsequently underwent surgical&#xD;
        resection at the Atrium Hospital in Heerlen. All patients were included in a prospectively&#xD;
        maintained database.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oesophageal cancer patients&#xD;
&#xD;
          -  initially treated with a preoperative dose of radiation in combination with&#xD;
             chemotherapy and subsequently undergone surgical resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were treated with definitive chemoradiation or palliative radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Lambin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

